Moderna Q2 net loss $(0.8)B, EPS $(1.97); norovirus vaccine misses interim endpoint

Moderna, Inc.

Q2 revenue $145M (flat YoY); GAAP net loss $(0.8)B, EPS $(1.97) vs $(2.13) in Q2 2025.
2026 guidance: targeting up to 10% revenue growth; year-end cash improved to $4.7-5.2B; R&D expense lowered to ~$2.9B.
Norovirus vaccine mRNA-1403 failed early success criteria at Phase 3 interim; enrolling additional cohort.
mFLUSIVA (flu vaccine) PDUFA date Aug 5, 2026; potential fifth approved product.
Appointed Ester Banque as CCO and Michael McDonnell to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.